Insulet Co. (NASDAQ:PODD) Shares Bought by Greenleaf Trust

Greenleaf Trust grew its holdings in shares of Insulet Co. (NASDAQ:PODD) by 4.2% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,783 shares of the medical instruments supplier’s stock after purchasing an additional 72 shares during the quarter. Greenleaf Trust’s holdings in Insulet were worth $415,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the business. Sunbelt Securities Inc. acquired a new stake in Insulet in the 1st quarter worth about $29,000. Blue Trust Inc. grew its holdings in Insulet by 84.1% in the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 58 shares during the period. International Assets Investment Management LLC acquired a new position in Insulet during the second quarter worth approximately $32,000. UMB Bank n.a. increased its position in Insulet by 81.0% during the second quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock worth $37,000 after purchasing an additional 81 shares during the last quarter. Finally, CVA Family Office LLC boosted its holdings in shares of Insulet by 138.1% in the 2nd quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier’s stock valued at $50,000 after purchasing an additional 145 shares during the last quarter.

Insulet Stock Performance

Insulet stock opened at $233.63 on Friday. The company has a debt-to-equity ratio of 1.36, a current ratio of 3.60 and a quick ratio of 2.71. The firm’s fifty day moving average price is $222.53 and its 200 day moving average price is $199.26. The company has a market capitalization of $16.36 billion, a price-to-earnings ratio of 70.80, a price-to-earnings-growth ratio of 4.42 and a beta of 1.21. Insulet Co. has a 12-month low of $128.68 and a 12-month high of $243.98.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $0.55 EPS for the quarter, missing the consensus estimate of $0.56 by ($0.01). Insulet had a return on equity of 30.73% and a net margin of 21.11%. The business had revenue of $488.50 million during the quarter, compared to analyst estimates of $488.00 million. During the same quarter last year, the firm posted $0.38 EPS. The company’s revenue was up 23.2% compared to the same quarter last year. On average, research analysts forecast that Insulet Co. will post 3.04 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on PODD. Barclays upped their price objective on Insulet from $200.00 to $220.00 and gave the stock an “equal weight” rating in a report on Monday, August 12th. UBS Group raised their price objective on Insulet from $211.00 to $223.00 and gave the stock a “neutral” rating in a report on Friday, August 9th. BTIG Research boosted their target price on Insulet from $250.00 to $260.00 and gave the stock a “buy” rating in a report on Monday, October 14th. Citigroup raised their price target on shares of Insulet from $250.00 to $275.00 and gave the company a “buy” rating in a report on Tuesday, October 1st. Finally, Raymond James boosted their price objective on shares of Insulet from $213.00 to $260.00 and gave the stock an “outperform” rating in a research note on Monday, October 14th. Three equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat, Insulet currently has a consensus rating of “Moderate Buy” and an average price target of $242.29.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.